concept
microarray
develop
earlier
concept
term
ambient
analyt
immunoassay
first
introduc
roger
ekin
follow
decad
microarray
first
success
realiz
dna
oligonucleotid
microarray
allow
quantif
mrna
express
level
thousand
gene
parallel
technolog
chang
mani
aspect
biolog
research
though
extrem
success
chemistri
dna
hybrid
preclud
applic
studi
protein
consid
major
drive
forc
cell
consist
view
mrna
profil
alway
correl
protein
express
report
mani
recent
mass
spectrometri
studi
therefor
protein
microarray
develop
highthroughput
tool
overcom
limit
dna
microarray
provid
versatil
platform
protein
function
analys
begin
develop
protein
array
technolog
bacteri
strain
cdna
express
librari
grid
grown
nylon
membran
follow
lysi
bacteria
immobil
total
protein
complement
howev
earli
attempt
limit
success
heterolog
protein
eg
human
protein
express
bacteria
yield
protein
lack
critic
eukaryot
posttransl
modif
denatur
condit
use
lyse
bacteri
host
result
improperli
fold
protein
protein
interest
purifi
away
thousand
unwant
bacteri
protein
densiti
array
low
long
research
group
began
report
effort
fabric
highdens
protein
microarray
purifi
protein
antibodi
order
improv
protein
stabil
preserv
nativ
conform
purifi
protein
mani
research
group
develop
varieti
surfac
featur
keep
protein
hydrat
protein
microarray
fabric
effort
includ
report
gelpad
chip
nanowel
chip
plasma
membraneco
chip
name
concept
microarray
develop
earlier
concept
term
ambient
analyt
immunoassay
first
introduc
roger
ekin
follow
decad
microarray
first
success
realiz
dna
oligonucleotid
microarray
allow
quantif
mrna
express
level
thousand
gene
parallel
technolog
chang
mani
aspect
biolog
research
though
extrem
success
chemistri
dna
hybrid
preclud
applic
studi
protein
consid
major
drive
forc
cell
consist
view
mrna
profil
alway
correl
protein
express
report
mani
recent
mass
spectrometri
studi
therefor
protein
microarray
develop
highthroughput
tool
overcom
limit
dna
microarray
provid
versatil
platform
protein
function
analys
begin
develop
protein
array
technolog
bacteri
strain
cdna
express
librari
grid
grown
nylon
membran
follow
lysi
bacteria
immobil
total
protein
complement
howev
earli
attempt
limit
success
heterolog
protein
eg
human
protein
express
bacteria
yield
protein
lack
critic
eukaryot
posttransl
modif
denatur
condit
use
lyse
bacteri
host
result
improperli
fold
protein
protein
interest
purifi
away
thousand
unwant
bacteri
protein
densiti
array
low
long
research
group
began
report
effort
fabric
highdens
protein
microarray
purifi
protein
antibodi
order
improv
protein
stabil
preserv
nativ
conform
purifi
protein
mani
research
group
develop
varieti
surfac
featur
keep
protein
hydrat
protein
microarray
fabric
effort
includ
report
gelpad
chip
nanowel
chip
plasma
membraneco
chip
name
real
breakthrough
report
fabric
yeast
proteom
microarray
snyder
group
studi
approxim
fulllength
yeast
orf
individu
express
yeast
protein
product
purifi
ntermin
gstfusion
protein
purifi
protein
robot
spot
singl
glass
slide
duplic
highdens
form
first
proteom
microarray
cover
yeast
proteom
recent
proteom
microarray
fabric
proteom
virus
bacteria
plant
human
basi
applic
protein
microarray
divid
two
class
analyt
function
protein
microarray
unlik
antibodi
array
analyt
microarray
function
protein
microarray
made
spot
purifi
protein
solid
surfac
therefor
use
direct
character
protein
function
protein
bind
properti
posttransl
modif
enzymesubstr
relationship
immun
respons
recent
reversephas
array
develop
tissu
cell
lysat
oppos
antibodi
use
construct
array
meanwhil
other
develop
variou
type
biochem
assay
conduct
use
protein
microarray
character
proteinbind
properti
includ
proteinprotein
dna
rna
lipid
interact
identifi
substrat
variou
type
enzym
protein
kinas
acetyltransferas
ubiquitin
sumo
ligas
via
coval
reaction
tabl
effort
clearli
demonstr
versatil
power
protein
microarray
technolog
system
biolog
proteom
tool
review
summar
recent
applic
protein
microarray
clinic
proteom
includ
biomark
identif
pathogenhost
interact
cancer
biolog
tabl
one
rapidli
grow
applic
protein
microarray
technolog
field
clinic
proteom
biomark
identif
applic
protein
microarray
stem
tradit
serolog
studi
focu
diagnost
identif
antibodi
patient
serum
sampl
antibodi
produc
part
immun
respons
infect
foreign
protein
even
person
protein
protein
protein
microarray
view
potenti
antigen
research
use
platform
identifi
autoantibodi
show
statist
signific
associ
infect
diseas
interest
gener
follow
approach
use
first
patient
sera
dilut
eg
incub
preblock
antigen
microarray
ie
protein
microarray
follow
stringent
wash
step
posit
signal
detect
use
antihuman
igg
igm
iga
antibodi
coupl
variou
fluorophor
detect
figur
compar
tradit
serolog
techniqu
elisa
agglutin
precipit
complementfix
fluoresc
antibodi
protein
microarraybas
serum
profil
much
sensit
perform
much
higher
throughput
anoth
signific
advantag
offer
unbias
platform
novel
biomark
identif
section
review
four
studi
illustr
histori
develop
protein
microarray
biomark
identif
zhu
et
al
fabric
first
viral
proteom
microarray
compos
everi
fulllength
protein
protein
fragment
encod
sar
coronaviru
sarscov
well
protein
five
addit
mammalian
coronavirus
microarray
use
screen
canadian
serum
sampl
collect
sar
outbreak
includ
sampl
confirm
sarscov
case
respiratori
ill
patient
healthcar
profession
antibodi
respons
quantifi
applic
antihuman
igg
igm
antibodi
coupl
differ
fluorophor
follow
measur
fluoresc
signal
intens
figur
identifi
potenti
biomark
serum
sampl
first
cluster
accord
rel
signal
intens
coronaviru
protein
unsupervis
fashion
see
data
analysi
section
serum
sampl
fell
two
major
group
upon
subsequ
comparison
clinic
data
larg
correl
either
sarsposit
sarsneg
sera
cluster
marker
five
fragment
sar
n
protein
associ
tightli
sar
infect
sar
sera
also
exhibit
statist
signific
bind
one
spike
protein
fragment
howev
protein
encod
coronavirus
also
show
signific
correl
determin
best
classifi
classif
model
two
differ
supervis
analysi
approach
k
nearest
neighbor
knn
logist
regress
lr
appli
n
protein
sar
cov
well
spike
protein
sar
cov
identifi
best
classifi
use
featur
serum
test
rel
nucleic
acid
diagnost
test
antipathogen
antibodi
potenti
detect
long
infect
take
advantag
serum
sampl
collect
sar
patient
recov
respiratori
diseas
day
diagnosi
use
probe
microarray
posit
signal
detect
antihuman
igg
igm
antibodi
figur
middl
panel
result
clearli
show
sar
cov
n
protein
could
readili
recogn
human
igg
antibodi
importantli
igm
antibodi
expect
howev
serum
sampl
collect
chines
patient
immedi
fever
detect
show
much
stronger
signal
igg
igm
profil
figur
left
panel
result
indic
protein
microarray
approach
capabl
detect
antipathogen
antibodi
serum
sampl
long
infect
well
detect
infect
earli
stage
infect
demonstr
antihuman
igm
profil
approach
develop
potenti
applic
virus
expect
great
impact
epidemiolog
studi
possibl
clinic
diagnos
similar
approach
appli
profil
humor
immun
respons
two
human
herpesvirus
epsteinbarr
viru
ebv
kaposi
sarcomaassoci
herpesviru
kshv
ebv
ubiquit
human
herpesviru
kshv
restrict
seropreval
virus
associ
malign
show
increas
frequenc
individu
coinfect
human
immunodefici
viru
type
zhu
hayward
group
gener
protein
microarray
consist
ebv
kshv
fulllength
protein
individu
express
purifi
yeast
instead
sera
plasma
antibodi
respons
ebv
kshv
examin
healthi
volunt
patient
b
cell
lymphoma
aidsrel
kaposi
sarcoma
lymphoma
experi
detect
igg
respons
known
antigen
well
tegument
protein
kshv
bbrf
ebv
ebv
ebv
ebv
earli
lytic
protein
iga
respons
ebv
viral
capsid
antigen
long
use
diagnost
tool
nasopharyng
carcinoma
also
found
iga
respons
healthi
hivinfect
patient
iga
respons
vca
found
frequent
elev
lymphoma
patient
individu
posit
comparison
igg
iga
respons
indic
iga
respons
much
higher
therefor
studi
demonstr
plasma
use
biomark
identif
immunoglobulin
respons
isotyp
iga
therefor
also
worth
test
demonstr
protein
microarray
could
also
use
identifi
new
biomark
autoimmun
diseas
chen
et
al
decid
appli
e
coli
proteom
microarray
profil
serum
sampl
collect
crohn
diseas
cd
ulcer
coliti
uc
patient
cd
uc
chronic
idiopath
clinic
heterogen
intestin
disord
collect
known
inflammatori
bowel
diseas
ibd
although
ibd
suggest
autoimmun
diseas
antimicrobi
antibodi
present
sera
ibd
patient
antigen
proven
valuabl
serolog
biomark
diagnosi
andor
prognosi
diseas
studi
protein
microarray
includ
protein
encod
commens
strain
screen
use
individu
serum
healthi
control
n
clinic
wellcharacter
patient
ibd
cd
uc
surprisingli
among
e
coli
protein
differenti
recogn
serum
antibodi
healthi
control
either
cd
uc
patient
protein
identifi
highli
immunogen
healthi
control
protein
identifi
highli
immunogen
cd
patient
protein
identifi
highli
immunogen
uc
patient
use
sever
statist
tool
identifi
two
set
serum
antibodi
novel
biomark
specif
distinguish
cd
healthi
control
accuraci
p
cd
uc
accuraci
p
studi
first
demonstr
use
highdens
highcont
proteom
microarray
discov
novel
serolog
biomark
also
first
effort
examin
human
immun
respons
entir
proteom
microbi
speci
diseas
context
protein
microarray
compos
individu
purifi
human
protein
would
ideal
tool
discoveri
novel
autoantigen
associ
autoimmun
diseas
take
autoimmun
hepat
aih
exampl
aih
chronic
necroinflammatori
diseas
human
liver
littl
known
etiolog
detect
nonorganspecif
liverrel
autoantibodi
use
immunoserolog
approach
wide
use
diagnosi
prognosi
howev
tradit
autoantigen
antisma
smooth
muscl
autoantibodi
antiana
antinuclear
autoantibodi
often
mixtur
complex
biolog
materi
unambigu
accur
detect
diseas
demand
identif
character
autoantigen
therefor
song
et
al
fabric
human
protein
microarray
nonredund
protein
express
purifi
gst
fusion
yeast
sever
advantag
associ
produc
human
protein
yeast
rather
bacteria
higher
solubl
higher
yield
larg
protein
eg
kd
better
preserv
conform
protein
protein
less
immunogen
produc
yeast
e
coli
howev
unlik
viral
bacteri
protein
microarray
signific
obstacl
use
human
protein
microarray
high
content
high
cost
exampl
human
protein
array
protein
exceed
per
array
order
reduc
cost
song
et
al
develop
twophas
strategi
identifi
new
biomark
aih
phase
design
rapid
select
candid
biomark
valid
phase
ii
figur
phase
aih
control
serum
sampl
select
individu
use
probe
human
protein
microarray
dilut
follow
detect
bound
human
autoantibodi
use
antihuman
igg
antibodi
statist
analysi
reveal
candid
autoantigen
valid
candid
avoid
potenti
overfit
problem
see
especi
like
deal
small
sampl
size
protein
posit
control
repurifi
build
larg
number
lowcost
small
array
phase
ii
valid
array
sequenti
probe
serum
sampl
use
phase
serum
sampl
obtain
addit
aih
primari
biliari
cirrhosi
pbc
hepat
b
hb
hepat
c
hc
system
lupu
erythematosu
sle
primari
syndrom
pss
rheumatoid
arthriti
ra
patient
neg
control
also
includ
serum
sampl
patient
suffer
type
sever
diseas
sampl
healthi
subject
three
new
antigen
dutpas
identifi
highli
aihspecif
biomark
sensit
albalik
dutpas
valid
addit
aih
sampl
doubleblind
design
final
demonstr
new
biomark
could
readili
appli
elisabas
assay
clinic
diagnosi
prognosi
studi
repres
new
paradigm
biomark
identif
use
protein
microarray
three
reason
first
manag
number
candid
biomark
rapidli
identifi
low
cost
fewer
expens
protein
microarray
highcont
need
first
phase
twophas
strategi
second
use
small
array
compris
select
candid
protein
valid
step
rapidli
carri
much
larger
cohort
lower
cost
valid
step
extrem
import
avoid
overfit
problem
associ
statist
analysi
biomark
classifi
identif
especi
deal
small
cohort
eg
overfit
problem
statist
model
describ
random
error
nois
instead
underli
relationship
gener
occur
biomark
identif
system
excess
complex
mani
individualtoindividu
variat
rel
number
sampl
use
result
biomark
overfit
gener
poor
predict
perform
therefor
test
addit
larger
cohort
doubleblind
design
effect
way
rule
overfit
biomark
third
author
develop
elisabas
assay
examin
perform
valid
biomark
addit
sampl
newli
identifi
biomark
serv
translat
step
toward
clinic
practic
addit
seen
seri
studi
employ
pathogen
protein
microarray
profil
serolog
respons
follow
infect
exampl
protein
microarray
develop
bacteria
virus
biomark
identif
variou
infecti
diseas
studi
clearli
demonstr
power
protein
microarray
identif
potenti
biomark
howev
sever
shortcom
repeatedli
seen
studi
instanc
mani
array
fabric
use
protein
translat
e
coli
lysat
without
purif
protein
contamin
unwant
e
coli
protein
sensit
assay
like
reduc
due
high
immunogen
result
e
coli
lysat
use
block
reagent
allevi
problem
also
problemat
mani
studi
identifi
biomark
valid
addit
cohort
therefor
possibl
overfit
complet
rule
emerg
applic
protein
microarray
field
clinic
proteom
unbias
proteomewid
survey
import
player
involv
pathogenhost
interact
identifi
factor
encod
either
pathogen
host
potenti
develop
novel
therapeut
target
protein
microarray
serv
ideal
platform
purpos
protein
microarray
fabric
host
pathogen
use
identifi
direct
pathogenhost
interact
strategi
particular
use
investig
virushost
interact
enter
host
cell
viral
genom
encod
protein
direct
physic
contact
host
biolog
materi
discuss
section
interact
investig
multipl
level
rnaprotein
interact
enzymesubstr
relationship
proteinprotein
interact
zhu
et
al
describ
first
studi
use
yeast
proteom
microarray
identifi
host
factor
affect
replic
brome
mosaic
viru
bmv
plantinfect
rna
viru
also
replic
cerevisia
previou
studi
shown
positivestrand
rna
viru
encod
trnalik
structur
rna
genom
clamp
adenin
motif
cam
requir
packag
genom
capsid
identifi
crucial
host
protein
interfer
viral
packag
process
camcontain
rna
stemloop
structur
incub
yeast
proteom
microarray
presenc
equal
amount
mutat
cam
hairpin
use
fluoresc
signal
intens
ratio
top
hit
identifi
valid
use
vitro
gelshift
assay
two
valid
candid
protein
pseudouridin
synthas
actin
patch
protein
select
character
tobacco
plant
protein
modestli
reduc
bmv
genom
plusstrand
rna
accumul
dramat
inhibit
bmv
system
spread
plant
also
prevent
encapsid
bmv
rna
plant
reassembl
bmv
virion
vitro
work
signific
establish
first
rnabind
assay
proteom
microarray
demonstr
util
protein
microarray
identifi
import
player
involv
pathogenhost
interact
cours
evolut
virus
success
exploit
host
via
develop
arsen
hijack
host
form
dna
protein
develop
effect
antivir
one
must
understand
molecular
mechan
virus
exploit
host
machineri
use
human
herpesvirus
infect
differ
tissu
caus
distinct
diseas
rang
mild
cold
sore
pneumon
birth
defect
cancer
howev
confront
mani
challeng
infect
host
includ
reprogram
cellular
gene
express
sens
cellcycl
phase
modifi
cellcycl
progress
reactiv
lytic
life
cycl
produc
new
virion
spread
infect
hand
mani
lytic
cycl
gene
involv
replic
viral
genom
eg
ortholog
serinethreonin
protein
kinas
highli
conserv
across
herpesviru
famili
therefor
becam
attract
hypothesi
share
substrat
target
ortholog
viral
kinas
would
reveal
host
pathway
critic
replic
across
herpesviru
famili
test
hypothesi
li
et
al
employ
human
protein
microarray
author
purifi
four
ortholog
kinas
encod
ebv
kshv
hcmv
perform
kinas
reaction
human
protein
microarray
describ
previous
identifi
share
substrat
like
everi
largescal
screen
next
challeng
select
candid
would
worth
pursu
author
appli
gene
ontolog
go
string
analys
http
stringdborg
databas
known
predict
proteinprotein
interact
candid
found
highli
connect
cluster
protein
strikingli
protein
known
involv
dna
damag
respons
ddr
figur
host
ddr
known
import
mani
virus
includ
human
herpesvirus
relev
virusinduc
tumorigenesi
narrow
list
singl
candid
indepth
character
author
reason
virus
like
target
upstream
master
regul
trigger
dna
damag
respons
basi
literatur
search
structur
cluster
tatinteract
protein
emerg
excel
candid
followup
upstream
ddr
pathway
candid
cluster
serv
master
regul
ddr
via
activ
atm
autophosphoryl
activ
acetyl
regul
chromatin
dynam
via
histon
acetyl
import
shown
virus
inde
author
observ
knock
ebvinfect
b
cell
ebv
lytic
replic
greatli
reduc
next
author
appli
seri
cellbas
assay
show
ebv
replic
activ
kinas
trigger
ebvinduc
ddr
also
mediat
induct
viral
lytic
gene
express
final
author
demonstr
also
requir
effici
lytic
replic
hcmv
kshv
work
illustr
valu
highthroughput
unbias
approach
discoveri
conserv
viral
target
host
potenti
develop
novel
therapeut
target
antivir
current
drug
avail
treat
herpesviru
infect
viral
escap
mutant
develop
result
extens
use
limit
repertoir
herpesviru
protein
kinas
attract
antivir
drug
target
howev
develop
broadli
effect
drug
target
protein
kinas
requir
knowledg
common
cellular
substrat
inform
provid
common
substrat
identif
assist
design
assay
new
broadli
effect
antiherpesviru
therapeut
protein
microarray
also
serv
conveni
tool
profil
proteinprotein
interactom
pathogen
host
recent
exampl
hayward
colleagu
survey
interactom
kshvencod
virul
factor
lana
human
host
use
human
protein
microarray
order
identifi
host
protein
recogn
lana
lana
function
latent
infect
cell
essenti
particip
kshv
genom
replic
driver
dysregul
cell
growth
although
yeast
twohybrid
screen
glutathion
stransferas
gst
affin
immunoprecipit
ip
assay
chromatographi
coupl
mass
spectroscopi
appli
identif
lana
bind
protein
approach
strength
weak
tend
identifi
differ
set
protein
studi
author
use
purifi
flagtag
lana
appli
human
protein
microarray
identifi
potenti
bind
partner
mani
previous
unknown
protein
valid
coimmunoprecipit
includ
protein
phosphatas
replic
protein
rpa
xpa
although
human
papillomaviru
hpv
tat
human
cytomegaloviru
hcmv
interact
induc
degrad
lanaassoci
retain
acetyltransferas
activ
show
increas
stabil
observ
line
studi
describ
previou
section
show
play
posit
role
kshv
lytic
replic
hand
identif
rpa
lana
interact
partner
suggest
lana
may
play
role
regul
length
host
telomer
known
essenti
replic
cellular
telomer
dna
test
hypothesi
author
perform
chip
assay
antibodi
use
primer
specif
telomer
region
found
presenc
lana
drastic
reduc
recruit
host
telomer
impact
protein
level
rpa
complex
observ
rais
possibl
lana
might
impact
telomer
length
use
southern
blot
analysi
termin
restrict
fragment
standard
method
quantifi
telomer
length
author
demonstr
averag
length
telomer
shorten
least
lanaexpress
endotheli
cell
kshvinfect
primari
effus
lymphoma
cell
mani
interest
question
remain
answer
lana
block
rpa
complex
recruit
telomer
achiev
via
direct
competit
sinc
lana
also
ssdna
bind
protein
lana
serv
kinas
sink
rpa
complex
regul
rpa
recruit
via
phosphoryl
flip
side
human
factor
interest
use
survey
viru
protein
microarray
identifi
import
viral
factor
similar
ubiquityl
pathway
sumoyl
involv
seri
sequenti
enzymat
reaction
conjug
sumo
lysin
residu
substrat
protein
previou
studi
shown
latent
lytic
ebv
protein
interact
sumo
system
noncoval
sumoebv
protein
interact
occur
via
sumo
interact
motif
sim
target
protein
comprehens
identifi
addit
ebv
protein
bind
sumo
li
et
al
perform
proteinbind
assay
human
previous
describ
ebv
proteom
microarray
identifi
total
protein
includ
conserv
viral
kinas
mutat
potenti
sim
nand
ctermini
chang
intracellular
local
nuclear
cytoplasm
mutat
ntermin
sim
remain
predominantli
nuclear
mutat
ctermin
sim
yield
intermedi
phenotyp
nuclear
cytoplasm
stain
author
also
found
abolish
sumoyl
ebv
lytic
cycl
transactiv
zta
inhibitori
effect
zta
sumoyl
depend
sumo
bind
kinas
activ
global
profil
protein
sumoyl
also
suppress
sim
kinasedead
mutant
furthermor
bglf
interact
sumo
requir
induc
cellular
dna
damag
respons
enhanc
product
extracellular
viru
ebv
lytic
replic
identif
pathogen
protein
interact
human
factor
also
appli
understand
mechan
bacteri
infect
margarit
other
har
power
protein
microarray
identifi
protein
express
two
speci
streptococcu
gramposit
bacteria
streptococcu
pyogen
agalactia
interact
human
factor
known
mediat
pathogenesi
rather
develop
wholeproteom
array
use
bioinformat
approach
predict
protein
present
cellular
surfaceand
thu
like
play
role
infect
use
list
protein
develop
array
also
care
consid
human
probe
would
use
choos
three
human
ligand
fibronectin
fibrinogen
bind
protein
known
play
import
role
colon
infect
process
bind
experi
conduct
use
streptococc
array
human
protein
probe
identifi
known
interact
previous
report
well
newli
identifi
streptococc
protein
mani
confirm
farwestern
blot
analysi
novel
protein
includ
protein
unknown
function
well
relat
protein
term
fib
protein
use
domain
map
identifi
region
fib
protein
requir
interact
human
ligand
interestingli
sera
sampl
patient
agalactia
infect
show
high
titer
fibspecif
antibodi
indic
protein
highli
express
infect
work
determin
role
protein
infect
whether
emerg
suitabl
drug
target
fight
pathogen
streptoccu
infect
summari
studi
demonstr
power
protein
microarray
discoveri
novel
molecular
mechan
underli
hostpathogen
interact
variou
level
recent
year
highthroughput
approach
shotgun
mass
spectrometri
genomewid
rnai
screen
yeast
twohybrid
appli
understand
hostpathogen
interact
howev
protein
microarray
approach
provid
versatil
platform
singl
approach
identifi
multipl
type
direct
interact
pathogen
host
includ
proteinprotein
interact
rnaprotein
interact
enzymesubstr
interact
past
five
year
rapid
develop
genomewid
sequenc
technolog
ie
nextgen
sequenc
reveal
heterogen
natur
tumor
howev
clinic
diagnosi
tumor
larg
still
depend
morpholog
pattern
fact
tumor
indistinguish
morpholog
vastli
differ
clinic
outcom
suggest
molecular
heterogen
patient
tumor
cell
better
understood
effect
therapi
develop
therefor
futur
cancer
treatment
tailor
molecular
therapi
specif
individu
requir
new
class
proteom
profil
technolog
wide
adopt
technolog
protein
microarray
meet
need
profil
function
state
tumor
cancer
biomark
identif
wide
adopt
approach
determin
statu
signal
pathway
tumor
cell
base
immunoblot
analysi
antibodi
recogn
phosphoryl
protein
transform
lowthroughput
immunoblot
highthroughput
format
haab
et
al
first
report
develop
antibodi
microarray
technolog
individu
commerci
antibodi
spot
glass
high
densiti
technolog
allow
simultan
detect
multipl
antigen
present
complex
biolog
sampl
cell
tissu
bodi
fluid
term
revers
phase
protein
microarray
propos
liotta
petricoin
colleagu
array
lysat
cell
tissu
immobil
array
surfac
rather
antibodi
use
phosphoproteinspecif
antibodi
array
use
interrog
phosphoryl
state
protein
present
mixtur
proxi
signal
statu
tumor
sever
ongo
clinic
trial
current
util
revers
phase
protein
microarray
obviou
advantag
approach
allow
evalu
state
multipl
compon
signal
pathway
even
though
cell
lyse
fabric
microarray
requir
minimum
amount
sampl
multipl
clinic
sampl
biopsi
sampl
tumor
bodi
fluid
print
seri
ident
array
analyz
parallel
use
commerci
avail
antiphosphoprotein
specif
antibodi
exampl
petricoin
cowork
use
cancer
cell
lysat
repres
patient
sampl
obtain
children
oncolog
group
intergroup
rhabdomyosarcoma
studi
ir
fabric
revers
phase
microarray
rhabodymyosarcoma
rare
childhood
cancer
aris
undifferenti
muscl
progenitor
cell
although
current
treatment
yield
high
diseasefre
surviv
rate
reason
treatment
failur
remain
onethird
patient
unknown
identif
biomark
allow
distinguish
patient
respond
tradit
therapi
would
help
identifi
patient
best
suit
altern
therapi
also
potenti
drug
target
revers
phase
array
therefor
use
platform
detect
phosphoryl
statu
protein
thought
underli
whether
rhabdomyosarcoma
subtyp
respons
standard
chemotherapi
regimen
use
phosphositespecif
antibodi
author
identifi
higher
phosphoryl
level
aktmtor
pathway
compon
patient
poor
surviv
outcom
network
analysi
base
data
known
pathway
inform
use
find
hand
patient
good
treatment
outcom
show
mtor
pathway
suppress
togeth
find
suggest
pharmacolog
induc
mtor
pathway
suppress
could
result
improv
outcom
patient
fail
respond
standard
chemotherapi
regimen
author
proceed
test
hypothesi
use
mous
xenograft
model
rhabdoymyosarcoma
cell
line
known
mtor
pathway
inhibitor
found
treatment
inhibitor
result
reduc
phosphoryl
protein
identifi
protein
microarray
studi
well
inhibit
tumor
growth
result
suggest
mtor
pathway
inhibitor
may
potenti
way
improv
treatment
outcom
patient
fail
respond
standard
chemotherapi
regimen
addit
demonstr
power
tumor
cell
lysat
array
identifi
specif
patient
subpopul
could
benefit
tailor
therapi
well
identifi
specif
molecul
target
develop
test
therapi
howev
sever
major
problem
revers
phase
array
approach
first
wellcharacter
antibodi
avail
great
major
human
protein
second
sever
recent
studi
suggest
mani
commerci
avail
monoclon
antibodi
mab
may
even
recogn
purport
target
crossreact
extens
cellular
antigen
third
antibodi
crossreact
even
press
problem
diagnost
therapeut
applic
underlin
recent
withdraw
sever
mabbas
pharmaceut
market
final
approach
requir
prior
knowledg
phosphoprotein
evalu
result
ideal
platform
discoveri
novel
biomark
current
screen
breast
cancer
use
mammogram
detect
breast
cancer
falseposit
mammogram
lead
unnecessari
biopsi
identif
biomark
would
allow
earli
detect
breast
cancer
could
provid
noninvas
low
cost
method
could
improv
patient
outcom
one
promis
categori
cancer
biomark
autoantibodi
tumor
antigen
offer
better
stabil
specif
eas
purif
eas
detect
compar
serum
protein
order
identifi
autoantibodi
tumor
antigen
associ
breast
cancer
anderson
et
al
use
protein
array
contain
candid
tumor
antigen
appli
breast
cancer
patient
control
serum
sampl
identifi
differ
human
antibodi
repertoir
could
use
biomark
custom
protein
array
term
nappa
array
nucleic
acid
protein
programm
array
fabric
spot
cdna
encod
target
protein
featur
array
protein
transcrib
translat
cellfre
system
immobil
encod
epitop
tag
thu
bypass
protein
purif
process
addit
author
use
threephas
screen
approach
home
best
candid
breast
cancer
biomark
first
phase
use
array
full
set
tumor
antigen
order
elimin
uninform
autoantibodi
present
similar
level
earli
breast
cancer
patient
healthi
women
subtract
antigen
protein
set
reduc
allow
fabric
smaller
array
next
phase
offer
benefit
reduc
cost
fewer
fals
posit
second
phase
sera
patient
invas
earli
breast
cancer
benign
breast
diseas
compar
order
identifi
antigen
specif
earli
breast
cancer
absent
benign
breast
diseas
result
antigen
third
phase
set
valid
antigen
list
find
antigen
maintain
high
level
specif
blind
valid
assay
includ
protein
known
autoantigen
focus
protein
went
show
high
express
breast
cancer
cell
line
western
blot
well
significantli
higher
autoantibodi
level
earli
breast
cancer
serum
case
compar
control
although
first
step
work
demonstr
power
protein
microarray
particular
programm
protein
microarray
identifi
biomark
earli
detect
breast
cancer
import
goal
identifi
cancer
biomark
defin
new
strategi
earli
diagnosi
allow
earli
intervent
current
therapi
improv
patient
surviv
rate
addit
sinc
cancerassoci
autoantibodi
often
target
protein
mutat
modifi
aberrantli
express
tumor
cell
could
also
consid
immunolog
report
could
uncov
molecular
event
underli
tumorigenesi
molecular
player
event
turn
may
best
place
start
effort
develop
novel
therapi
order
identifi
autoantibodi
biomark
could
act
indic
bladder
cancer
well
underli
molecular
patholog
contribut
diseas
orenespinero
turn
protein
array
strategi
use
invitrogen
protoarray
contain
purifi
human
protein
identifi
antibodi
tumorassoci
antigen
serum
compar
serum
sampl
collect
patient
bladder
cancer
control
patient
without
bladder
cancer
identifi
differenti
express
protein
among
select
clusterin
dynamin
valid
base
part
known
role
cancer
biolog
use
immunohistochemistri
custom
tissu
microarray
compris
bladder
cancer
tumor
sampl
found
reduc
express
level
clusterin
muscl
invas
bladder
tumor
compar
nonmuscl
invas
tumor
hand
found
low
protein
express
dynamin
associ
increas
tumor
stage
grade
higher
recurr
rate
surgeri
well
shorter
surviv
paradox
followup
test
reveal
lower
express
level
dynamin
clusterin
associ
diseas
contrast
protein
array
result
show
increas
autoantibodi
level
protein
among
bladder
cancer
patient
compar
control
despit
contradictori
find
author
demonstr
signific
associ
dynamin
clusterin
express
level
bladder
cancer
diseas
progress
could
potenti
allow
use
inform
biomark
clinic
well
potenti
drug
target
work
demonstr
power
protein
microarray
identif
autoantibodi
tumor
associ
antigen
applic
discoveri
cancer
biomark
cell
surfac
especi
mammalian
cell
surfac
heavili
coat
complex
polyand
oligosaccharid
glycan
implic
mani
function
celltocel
commun
hostpathogen
interact
cell
matrix
interact
aberr
glycosyl
usual
indic
onset
specif
diseas
cancer
hand
tool
use
studi
glycosyl
liquid
chromatographi
lc
mass
spectrometri
capillari
electrophoresi
flow
cytometri
take
advantag
specif
glycanbind
properti
lectin
parallel
analysi
capabl
microarray
other
develop
lectin
microarray
technolog
profil
glycan
highthroughput
fashion
although
lectin
microarray
earli
report
compos
small
number
lectin
later
report
highcont
lectin
microarray
compos
uniqu
commerci
lectin
fabric
use
profil
access
surfac
glycan
mammalian
cell
total
human
cell
line
label
appli
lectin
microarray
binari
algorithm
develop
gener
glycan
signatur
cell
line
result
hierarch
cluster
base
access
glycan
composit
compar
glycan
profil
breast
cancer
cell
line
cancer
stemlik
cell
deriv
three
lectin
name
lel
aal
wga
found
specif
recogn
cell
deriv
confirm
result
author
first
employ
lelconjug
bead
purifi
away
normal
cell
cancer
stemlik
cell
estim
cell
popul
cell
popul
mean
enrich
cancer
stemlik
cell
next
use
mous
model
test
enrich
cancer
stemlik
cell
show
two
week
follow
inject
leldeplet
cancer
stemlik
cell
enrich
cultur
averag
tumor
size
bigger
control
group
inject
similar
number
regular
cell
studi
demonstr
util
lectin
microarray
identif
novel
cell
surfac
marker
cancer
stemlik
cell
subsequ
allow
enrich
cancer
stemlik
cell
affin
lectin
usual
low
kd
rang
process
cell
bind
assay
lectin
microarray
analyt
low
affin
may
wash
away
immobil
lectin
especi
deal
live
cell
order
overcom
problem
research
modifi
lectin
microarray
technolog
mani
way
one
exampl
antibodyassist
lectin
profil
alp
develop
detect
glycoprotein
low
concentr
kuno
et
al
use
method
analyz
glycan
structur
protein
hpod
propos
enhanc
metastat
potenti
glioblastoma
cell
hpod
protein
complex
first
ipenrich
appropri
antibodi
incub
lectin
array
identifi
associ
glycan
addit
modif
lectin
microarray
platform
use
evanescentfield
activ
fluoresc
detect
system
allow
labelfre
real
time
detect
sinc
evanesc
field
gener
within
nm
background
signal
low
wash
step
necessari
report
detect
system
far
highest
sensit
among
lectin
microarray
detect
system
report
detect
limit
pm
rang
final
li
et
al
report
twophas
discoveri
valid
approach
improv
sensit
lectin
microarray
technolog
cancer
biomark
discoveri
prostat
cancer
first
pool
tissu
sampl
group
gener
mix
equal
amount
tissu
protein
four
case
normal
nonaggress
cancer
aggress
cancer
metastasi
group
first
phase
discoveri
phase
prostat
specif
antigen
psa
membran
metalloendopeptidas
mme
protein
extract
tissu
group
use
antitot
psa
antibodi
antimm
mab
respect
incub
ipe
psa
mme
protein
lectin
microarray
captur
psa
mme
protein
detect
antipsa
antimm
mab
comparison
signal
group
pool
tissu
reveal
fraction
psa
oglycosyl
recogn
jacalin
detect
sna
well
fraction
mme
modifi
either
galnac
glcnac
highli
elev
aggress
prostat
cancer
metastat
prostat
cancer
group
result
confirm
immunosorb
assay
phase
ii
psa
mme
first
captur
ecl
plate
coat
antipsa
antimm
mab
follow
detect
biotinyl
lectin
studi
demonstr
power
adapt
protein
microarray
detect
even
lowaffin
interact
lectin
glycan
recent
year
wit
tremend
growth
use
protein
microarray
address
import
question
field
clinic
proteom
area
biomark
identif
recent
research
focus
either
infect
autoimmun
diseas
believ
protein
microarray
especi
function
protein
microarray
wide
use
identif
cancer
biomark
near
futur
inde
recent
advanc
immunoproteom
highthroughput
technolog
suggest
autoantibodi
repertoir
cancer
patient
might
quit
differ
compar
healthi
subject
lead
hypothesi
autoantigen
might
identifi
biomark
cancer
diagnosi
well
cancer
prognosi
ideal
human
protein
microarray
develop
purpos
cover
entir
human
proteom
order
enabl
comprehens
screen
autoantigen
knowledg
fabric
human
proteom
microarray
best
coverag
howev
hundr
thousand
serum
sampl
need
screen
biomark
cost
use
human
proteom
microarray
accumul
rapidli
effect
strategi
overcom
obstacl
appli
twophas
strategi
describ
aih
studi
expect
strategi
becom
popular
near
futur
final
expect
function
protein
microarray
use
readout
obtain
reaction
profil
collect
activ
variou
type
enzym
kinas
acetyltransferas
ubiquitin
sumo
ligas
cancer
tissu
compar
ptm
profil
obtain
cancer
healthi
tissu
allow
us
identifi
biomark
gain
new
insight
molecular
mechan
diseas
principl
serum
profil
assay
perform
function
protein
microarray
function
protein
microarray
compos
hundr
thousand
individu
purifi
protein
first
block
bsa
pb
buffer
dilut
serum
sampl
incub
microarray
typic
rt
hr
extens
wash
bound
antibodi
eg
human
igg
iga
igm
detect
antihuman
immunoglobulin
antibodi
follow
signal
amplif
step
fluoresc
label
secondari
antibodi
detect
immunoglobulin
isotyp
multiplex
differ
fluorophor
illustr
exampl
igg
igm
profil
obtain
serum
sampl
sarscovinfect
patient
sampl
fp
collect
immedi
follow
detect
fever
patient
beij
sampl
dp
collect
recov
sar
patient
toronto
signal
upper
panel
bsa
control
detect
antihuman
igg
signal
lower
panel
two
patient
sampl
detect
antihuman
igm
scheme
twophas
strategi
biomark
identif
human
autoimmun
diseas
phase
small
cohort
use
rapidli
identifi
group
candid
biomark
via
serum
profil
assay
human
protein
microarray
high
cost
small
number
microarray
need
cost
experi
rel
low
phase
ii
focus
protein
microarray
low
cost
fabric
spot
purifi
candid
protein
much
larger
cohort
assay
array
doubl
blind
fashion
valid
candid
identifi
phase
identif
relev
candid
indepth
vivo
studi
assist
go
analysi
share
substrat
conserv
herpesviru
kinas
plug
string
databas
highli
connect
cluster
protein
reveal
known
play
role
ddr
base
literatur
topolog
cluster
emerg
promis
candid
protein
node
color
code
function
class
protein
involv
ddr
color
red
small
blue
circl
adjac
protein
node
indic
protein
herpesviru
associ
small
pink
circl
indic
protein
associ
virus
edg
protein
repres
known
predict
connect
proteinprotein
interact
catalyt
reaction
enzymesubstr
relationship
autoimmun
hepat
serum
autoantibodi
detect
human
array
compris
purifi
protein
primari
biliari
cirrhosi
serum
autoantibodi
detect
human
array
compris
purifi
protein
syndrom
saliva
autoantibodi
detect
human
array
compris
purifi
protein
cancer
breast
cancer
serum
autoantibodi
detect
human
array
compris
candid
tumor
antigen
cancer
stemlik
cell
glycan
signatur
identifi
use
array
lectin
bladder
cancer
serum
autoantibodi
detect
human
array
compris
purifi
protein
rhabdomyosarcoma
phosphoryl
statu
protein
detect
human
array
spot
cancer
cell
lysat
